A massive valuation for a "seed" round can be misleading. Often, insiders have participated in several unannounced, cheaper tranches. The headline number is just the final, most expensive tier, used to create FOMO and set a high watermark for new investors.

Contrary to founder belief, raising too much money is incredibly dangerous. It fosters a lack of discipline and operational "indigestion." A high valuation also sets a dangerous precedent, making future fundraising difficult as new investors are loath to lead a down round, effectively trapping the company.

The first question in any fundraising or M&A discussion is always, 'What was your last round price?' An inflated number creates psychological friction and can halt negotiations before they begin. Founders should optimize for a valuation that allows for a clear up-round, not just the highest price today.

Accepting too high a valuation can be a fatal error. The first question in any subsequent fundraising or M&A discussion will be about the prior round's price. An unjustifiably high number immediately destroys the psychology of the new deal, making it nearly impossible to raise more capital or sell the company, regardless of progress.

Valuations don't jump dramatically; they 'sneak up on you.' An investor might balk at a $45M cap when they expected $40M. But the fear of missing a potential unicorn is stronger than the desire for a slightly better price, causing a gradual, batch-over-batch inflation of valuation norms.

Brex's acquisition, despite being a lower valuation than its previous round, is a heroic success. The negative feelings associated with a "hubristic financing" round are fleeting compared to the massive value created, proving the ultimate outcome outweighs temporary valuation optics.

Venture rounds are compressing and conflating, with massive "seed" rounds of $30M+ essentially combining a seed and Series A. This sets a dangerous trap: the expectations for your next funding round will be equivalent to those of a traditional Series B company, dramatically raising the bar for growth.

Beyond outright fraud, startups often misrepresent financial health in subtle ways. Common examples include classifying trial revenue as ARR or recognizing contracts that have "out for convenience" clauses. These gray-area distinctions can drastically inflate a company's perceived stability and mislead investors.

Setting an overly optimistic valuation for a pre-revenue friends-and-family round can create a 'valuation trap.' If you later need a structured seed round from an accelerator with standardized (and likely lower) terms, your initial investors may veto the necessary 'down round,' killing the deal and your access to capital.